NASDAQ:MLNT - Melinta Therapeutics Stock Price, News, & Analysis

Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."

Melinta Therapeutics shares reverse split on Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 21st 2019. An investor that had 100 shares of Melinta Therapeutics stock prior to the reverse split would have 20 shares after the split.

Melinta Therapeutics Inc (NASDAQ:MLNT) announced its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($6.90) earnings per share for the quarter, missing analysts' consensus estimates of ($5.70) by $1.20. The biotechnology company had revenue of $12.02 million for the quarter, compared to analyst estimates of $12.06 million. Melinta Therapeutics had a negative net margin of 163.01% and a negative return on equity of 60.83%. View Melinta Therapeutics' Earnings History.

Melinta Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Melinta Therapeutics.

7 analysts have issued twelve-month target prices for Melinta Therapeutics' shares. Their forecasts range from $40.00 to $75.00. On average, they expect Melinta Therapeutics' stock price to reach $62.9167 in the next year. This suggests a possible upside of 1,449.7% from the stock's current price. View Analyst Price Targets for Melinta Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Melinta Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Melinta Therapeutics.

News headlines about MLNT stock have trended neutral on Sunday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Melinta Therapeutics earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the company's share price in the near term.

Melinta Therapeutics saw a increase in short interest in the month of February. As of February 15th, there was short interest totalling 2,245,682 shares, an increase of 90.6% from the January 31st total of 1,178,376 shares. Based on an average trading volume of 3,554,089 shares, the days-to-cover ratio is presently 0.6 days. Currently, 31.2% of the company's shares are sold short. View Melinta Therapeutics' Current Options Chain.

Some companies that are related to Melinta Therapeutics include resTORbio (TORC), Menlo Therapeutics (MNLO), BELLUS Health (BLUSF), Aratana Therapeutics (PETX), Galmed Pharmaceuticals (GLMD), Nature's Sunshine Products (NATR), Axovant Sciences (AXON), Ocular Therapeutix (OCUL), PhaseBio Pharmaceuticals (PHAS), Cue Biopharma (CUE), ProMetic Life Sciences (PFSCF), Neos Therapeutics (NEOS), Bellicum Pharmaceuticals (BLCM), Humanigen (HGEN) and Spring Bank Pharmaceuticals (SBPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Melinta Therapeutics investors own include Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), Celgene (CELG), Dynavax Technologies (DVAX), Novavax (NVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), Portola Pharmaceuticals (PTLA), TransEnterix (TRXC) and NVIDIA (NVDA).

Melinta Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.52%), First Manhattan Co. (1.69%), Dimensional Fund Advisors LP (1.38%), Dimensional Fund Advisors LP (6.90%), Millennium Management LLC (1.07%) and Fosun International Ltd (0.88%). Company insiders that own Melinta Therapeutics stock include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Institutional Ownership Trends for Melinta Therapeutics.

MLNT stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co. and Millennium Management LLC. View Insider Buying and Selling for Melinta Therapeutics.

MLNT stock was bought by a variety of institutional investors in the last quarter, including Fosun International Ltd, Two Sigma Investments LP, Assenagon Asset Management S.A., Boenning & Scattergood Inc., BlackRock Inc., Condor Capital Management, Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. Company insiders that have bought Melinta Therapeutics stock in the last two years include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Insider Buying and Selling for Melinta Therapeutics.

Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MLNT stock can currently be purchased for approximately $4.06.

Melinta Therapeutics has a market capitalization of $45.59 million and generates $96.43 million in revenue each year. The biotechnology company earns $-157,190,000.00 in net income (profit) each year or ($17.72) on an earnings per share basis. Melinta Therapeutics employs 290 workers across the globe.

The official website for Melinta Therapeutics is http://www.melinta.com.

Melinta Therapeutics' mailing address is 44 WHIPPANY ROAD, MORRISTOWN NJ, 07963. The biotechnology company can be reached via phone at 908-617-1309 or via email at [email protected]